Krebs Biochemicals & Industries Limited (NSE:KREBSBIO)
India · Delayed Price · Currency is INR 57.77
+0.23 (0.40%)
Sep 24, 2026, 3:26 PM IST
NSE:KREBSBIO Revenue
Krebs Biochemicals & Industries had revenue of 69.84M INR in the quarter ending June 30, 2026, with 27.42% growth. This brings the company's revenue in the last twelve months to 252.34M, down -29.72% year-over-year. In the fiscal year ending March 31, 2026, Krebs Biochemicals & Industries had annual revenue of 237.32M, down -45.21%.
Revenue (ttm)
252.34M
Revenue Growth
-29.72%
P/S Ratio
4.87
Revenue / Employee
1.78M
Employees
142
Market Cap
1.23B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 237.32M | -195.80M | -45.21% |
| Mar 31, 2025 | 433.12M | -71.10M | -14.10% |
| Mar 31, 2024 | 504.22M | -17.13M | -3.29% |
| Mar 31, 2023 | 521.34M | -75.69M | -12.68% |
| Mar 31, 2022 | 597.03M | 70.20M | 13.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valiant Laboratories | 3.06B |
| Amanta Healthcare | 2.91B |
| Balaxi Pharmaceuticals | 2.80B |
| Bafna Pharmaceuticals | 1.43B |
| Alpa Laboratories | 1.11B |
| Par Drugs and Chemicals | 1.09B |
| Vaishali Pharma | 1.08B |
| Brooks Laboratories | 831.87M |
Krebs Biochemicals & Industries News
- 1 year ago - Krebs Biochemicals & Industries halts production following order from Andhra Pradesh Pollution Control Board - Business Upturn